Beyond Antiplatelet Therapy: Advances in CAD/PAD Management

Antiplatelet therapy, the long-running standard of care for the management of stable coronary artery disease (CAD) and peripheral artery disease (PAD), is often insufficient to prevent secondary cardiovascular events and mortality. This initiative will explore the use of dual pathway inhibition (with specific agents and doses of anticoagulation therapy plus antiplatelet therapy), as a potential new treatment paradigm to enhance cardio protection across a wide range of patients with CAD and/or PAD.